Neoadjuvant Therapy for Rectal Cancer: Improved Tumor Response, Local Recurrence, and Overall Survival in Nonanemic Patients

医学 放化疗 贫血 结直肠癌 内科学 全直肠系膜切除术 外科 胃肠病学 癌症
作者
Ben Box,Ian Lindsey,James Wheeler,Bryan F. Warren,Chris Cunningham,Bruce George,N J McC Mortensen,A Jones
出处
期刊:Diseases of The Colon & Rectum [Lippincott Williams & Wilkins]
卷期号:48 (6): 1153-1160 被引量:25
标识
DOI:10.1007/s10350-004-0939-7
摘要

Preoperative, long-course chemoradiotherapy is recommended for rectal cancers involving or threatening the mesorectal resection margin, but tumor response is variable. Some highly radiosensitive cancers completely regress, leading to reduced local recurrence and improved survival. This study was designed to evaluate the influence of anemia during chemoradiotherapy on tumor response, local and distant recurrence, and overall survival.Mean hemoglobins during chemoradiotherapy of consecutive patients with rectal cancer undergoing chemoradiotherapy and surgery were calculated and ranked. Anemia was defined as lowest quartile for males and females. Tumor response was histologically quantified using rectal cancer regression grade.Of 100 patients, 5 females and 20 males were anemic. Nonanemic patients achieved better tumor response (54 percent regression Grade 1) than anemic patients (28 percent, P = 0.028). There were more locally advanced cancers in anemic (48 percent T4) compared with nonanemic patients (21 percent T4), but radiologic T stage did not influence tumor response (50 percent T3 vs. 43 percent T4 regression Grade 1, P = 0.53) or overall survival. Mesorectal margin positivity was less in nonanemic (15 percent) compared with anemic patients (36 percent, P = 0.021). At median follow-up of 39 months, nonanemic patients (7 percent) suffered less local recurrence than anemic patients did (38 percent, P = 0.003). Overall survival at two years was improved in nonanemic (91 percent) compared with anemic patients (64 percent, P = 0.021), but was similar for T3 and T4 patients.Patients with normal hemoglobin during chemoradiotherapy achieved better tumor response, less local recurrence, and improved overall survival compared with anemic patients, independent of radiologic T stage. Correcting anemia before chemoradiotherapy might improve tumor response and oncologic outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小小虾完成签到 ,获得积分10
刚刚
1秒前
王嘉文发布了新的文献求助20
1秒前
FashionBoy应助庄严采纳,获得10
1秒前
Zox完成签到,获得积分10
1秒前
Owen应助科研工具人采纳,获得10
2秒前
GSQ发布了新的文献求助20
3秒前
深情安青应助聪慧跳跳糖采纳,获得10
4秒前
yangzai发布了新的文献求助10
4秒前
求是发布了新的文献求助10
4秒前
怕黑寻梅完成签到,获得积分10
4秒前
ED应助ironsilica采纳,获得10
4秒前
大观天下发布了新的文献求助10
5秒前
5秒前
丘比特应助王王采纳,获得10
5秒前
7秒前
王嘉文完成签到 ,获得积分20
8秒前
orixero应助乔苏惠娜采纳,获得10
9秒前
xxx完成签到,获得积分20
10秒前
10秒前
10秒前
Rain完成签到,获得积分10
11秒前
11秒前
guo发布了新的文献求助10
12秒前
12秒前
Hailin完成签到,获得积分10
14秒前
共享精神应助GSQ采纳,获得10
14秒前
酷波er应助怕黑寻梅采纳,获得10
14秒前
蓝莓酱蘸橘子完成签到 ,获得积分10
14秒前
15秒前
15秒前
所所应助reborn采纳,获得10
15秒前
Rain发布了新的文献求助10
15秒前
17秒前
咖褐完成签到,获得积分10
17秒前
Ahuan完成签到,获得积分10
17秒前
上官若男应助六点一横采纳,获得10
17秒前
怕黑彩虹完成签到,获得积分10
17秒前
19秒前
求是完成签到,获得积分10
19秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961103
求助须知:如何正确求助?哪些是违规求助? 3507388
关于积分的说明 11135834
捐赠科研通 3239867
什么是DOI,文献DOI怎么找? 1790434
邀请新用户注册赠送积分活动 872400
科研通“疑难数据库(出版商)”最低求助积分说明 803152